Insider transactions

EDGAR

Lyell Immunopharma, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-19.

Open-market purchases (code P)
4 transactions, 5,618,704 shares
Sum of shares × price per share: 74,999,953.28
Open-market sales (code S)
29 transactions, 31,569 shares
Sum of shares × price per share: 612,747.03

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 55

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-10 Filed 2026-11-12Lee Gary K. Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)12915.93
2,054.97

Derived: shares × price per share. Exact value 2054.97.

16,091Direct (D) No
F1
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0001907345-26-000008 Read from the filing’s XML Dispute this row
2026-11-10 Filed 2026-11-12Bulis Veronica Sanchez Officer: VP, Corporate Controller
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)41615.93
6,626.88

Derived: shares × price per share. Exact value 6626.88.

14,383Direct (D) No
F1
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0002095702-26-000007 Read from the filing’s XML Dispute this row
2026-11-10 Filed 2026-11-12Hill Stephen J. Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8815.93
1,401.84

Derived: shares × price per share. Exact value 1401.84.

16,728Direct (D) No
F1
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0001866154-26-000008 Read from the filing’s XML Dispute this row
2026-11-10 Filed 2026-11-12Seely Lynn Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)54515.93
8,681.85

Derived: shares × price per share. Exact value 8681.85.

63,354Direct (D) No
F1
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0001327111-26-000008 Read from the filing’s XML Dispute this row
2026-11-04 Filed 2026-11-05ARCH Venture Fund XIII, L.P. 10% ownerARCH Venture Partners XIII, L.P. 10% ownerARCH Venture Partners XIII, LLC 10% ownerCRANDELL KEITH 10% ownerGILLIS STEVEN 10% ownerNELSEN ROBERT 10% ownerBurow Kristina 10% ownerBERNS PAUL L 10% ownerBYBEE CLINTON 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,321,26210.77
24,999,991.74

Derived: shares × price per share. Exact value 24999991.74.

3,747,790Indirect (I) See FootnoteNo
F1, F2
  • F1 These shares were purchased on November 4, 2026 pursuant to a securities purchase agreement dated November 3, 2026 at a price per share of $10.77.
  • F2 These shares are directly held by ARCH Venture Fund XIII, L.P. (ARCH XIII). ARCH Venture Partners XIII, L.P. (AVP XIII LP) is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (AVP XIII LLC) is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the AVP XIII LLC Committee Members). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Open filing 0001012975-26-001013 Read from the filing’s XML Dispute this row
2026-11-04 Filed 2026-11-05ARCH Venture Partners IX, LLC 10% ownerARCH Venture Fund IX, L.P. 10% ownerARCH Venture Partners IX, L.P. 10% ownerARCH Venture Fund IX Overage, L.P. 10% ownerARCH Venture Partners IX Overage, L.P. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,321,26210.77
24,999,991.74

Derived: shares × price per share. Exact value 24999991.74.

3,747,790Indirect (I) See FootnoteNo
F1, F2
  • F1 These shares were purchased on November 4, 2026 pursuant to a securities purchase agreement dated November 3, 2026 at a price per share of $10.77.
  • F2 These shares are directly held by ARCH Venture Fund XIII, L.P. (ARCH XIII). ARCH Venture Partners XIII, L.P. (AVP XIII LP) is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (AVP XIII LLC) is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the AVP XIII LLC Committee Members). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Open filing 0001012975-26-001014 Read from the filing’s XML Dispute this row
2026-10-12 Filed 2026-10-13Aguirre Jarrad Mattieu Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4228.63
3,641.86

Derived: shares × price per share. Exact value 3641.86.

19,857Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $8.54 to $8.63 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0002150331-26-000003 Read from the filing’s XML Dispute this row
2026-09-10 Filed 2026-09-10Aguirre Jarrad Mattieu Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (47,500) — exercise price 12.20
Acquired (A)47,5000—47,500Direct (D) No
F2
  • F2 12.5% of the option shares will vest on February 28, 2027, with the remaining option shares to vest in equal monthly installments over the following 42 months, subject to the reporting person providing service through the applicable vesting date.
Open filing 0002150331-26-000002 Read from the filing’s XML Dispute this row
2026-09-10 Filed 2026-09-10Shook David Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)50012.70
6,350

Derived: shares × price per share. Exact value 6350.00.

20,423Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $12.32 to $12.70 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0001959742-26-000003 Read from the filing’s XML Dispute this row
2026-08-21 Filed 2026-08-25Hill Stephen J. Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)98915.54
15,369.06

Derived: shares × price per share. Exact value 15369.06.

16,816Direct (D) No
F1
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0001866154-26-000006 Read from the filing’s XML Dispute this row
2026-08-21 Filed 2026-08-25Lee Gary K. Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,45715.54
22,641.78

Derived: shares × price per share. Exact value 22641.78.

16,220Direct (D) No
F1
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0001907345-26-000006 Read from the filing’s XML Dispute this row
2026-08-21 Filed 2026-08-25Seely Lynn Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9,58915.54
149,013.06

Derived: shares × price per share. Exact value 149013.06.

63,899Direct (D) No
F1
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0001327111-26-000006 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-11Lee Gary K. Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)13114.34
1,878.54

Derived: shares × price per share. Exact value 1878.54.

17,677Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.22 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0001907345-26-000004 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-11Bulis Veronica Sanchez Officer: VP, Corporate Controller
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)62114.34
8,905.14

Derived: shares × price per share. Exact value 8905.14.

14,799Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.20 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0002095702-26-000005 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-11Hill Stephen J. Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8914.34
1,276.26

Derived: shares × price per share. Exact value 1276.26.

17,805Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.27 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0001866154-26-000004 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-11Seely Lynn Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)39014.34
5,592.6

Derived: shares × price per share. Exact value 5592.60.

73,488Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.22 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0001327111-26-000004 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-27Innovative Cellular Therapeutics Holdings Ltd 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)44,0000—2,774,980Direct (D) No
F1, F2
  • F1 Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
  • F2 Reflects 2,818,980 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 44,000 shares transferred.
Open filing 0001140361-26-029817 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-27Innovative Cellular Therapeutics Holdings Ltd 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)38,5000—2,818,980Direct (D) No
F1, F2
  • F1 Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
  • F2 Reflects 2,857,480 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 38,500 shares transferred.
Open filing 0001140361-26-029791 Read from the filing’s XML Dispute this row
2026-07-17 Filed 2026-07-20Innovative Cellular Therapeutics Holdings Ltd 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1013.7
137

Derived: shares × price per share. Exact value 137.0.

2,857,480Direct (D) Yes
F1
  • F1 Reflects 2,857,490 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.
Open filing 0001140361-26-028955 Read from the filing’s XML Dispute this row
2026-07-16 Filed 2026-07-17Innovative Cellular Therapeutics Holdings Ltd 10% owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1013.73
137.3

Derived: shares × price per share. Exact value 137.30.

2,857,490Direct (D) Yes
F1
  • F1 Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.
Open filing 0001140361-26-028846 Read from the filing’s XML Dispute this row
2026-06-29 Filed 2026-07-01Innovative Cellular Therapeutics Holdings Ltd 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)76,0000—2,857,500Direct (D) No
F1, F2
  • F1 Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
  • F2 Reflects 2,933,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 76,000 shares transferred.
Open filing 0001140361-26-027140 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-18Innovative Cellular Therapeutics Holdings Ltd 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)66,5000—2,933,500Direct (D) No
F1, F2
  • F1 Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
  • F2 Reflects 3,000,000 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 66,500 shares transferred. All shares are held directly and registered in the name of the Reporting Person.
Open filing 0001140361-26-025796 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12Ramachandra Sumant Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (9,250) — exercise price 13.22
Acquired (A)9,2500—9,250Direct (D) No
F3
  • F3 The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Open filing 0001439368-26-000002 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12BRAWLEY OTIS W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (9,250) — exercise price 13.22
Acquired (A)9,2500—9,250Direct (D) No
F2
  • F2 The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Open filing 0001213029-26-000007 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12RIEFLIN WILLIAM JL Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (9,250) — exercise price 13.22
Acquired (A)9,2500—9,250Direct (D) No
F1
  • F1 The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Open filing 0001182471-26-000002 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12FRIEDMAN CATHY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (9,250) — exercise price 13.22
Acquired (A)9,2500—9,250Direct (D) No
F4
  • F4 The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Open filing 0001411874-26-000002 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12Bachleda Mark Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (9,250) — exercise price 13.22
Acquired (A)9,2500—9,250Direct (D) No
F1
  • F1 The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Open filing 0001887762-26-000002 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12NABEL ELIZABETH G Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (9,250) — exercise price 13.22
Acquired (A)9,2500—9,250Direct (D) No
F1
  • F1 The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Open filing 0001619929-26-000004 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-12Klausner Richard Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (9,250) — exercise price 13.22
Acquired (A)9,2500—9,250Direct (D) No
F3
  • F3 The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Open filing 0001591178-26-000002 Read from the filing’s XML Dispute this row
2026-06-10 Filed 2026-06-11Shook David Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,97712.64
24,989.28

Derived: shares × price per share. Exact value 24989.28.

20,923Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan.
Open filing 0001959742-26-000002 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-06-15Bulis Veronica Sanchez Officer: VP, Corporate Controller
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)21718.91
4,103.47

Derived: shares × price per share. Exact value 4103.47.

15,420Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0002095702-26-000004 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-06-15Seely Lynn Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)38818.91
7,337.08

Derived: shares × price per share. Exact value 7337.08.

73,878Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.15 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0001327111-26-000003 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-06-15Lee Gary K. Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)13018.92
2,459.6

Derived: shares × price per share. Exact value 2459.60.

17,808Direct (D) No
F1, F2, F3
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  • F3 Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan.
Open filing 0001907345-26-000003 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-06-15Hill Stephen J. Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8918.92
1,683.88

Derived: shares × price per share. Exact value 1683.88.

17,894Direct (D) No
F1, F2, F3
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  • F3 Includes 188 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan.
Open filing 0001866154-26-000003 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-16Shah Smital Officer: Chief Fin. and Bus. Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (140,000) — exercise price 25.50
Acquired (A)140,0000—140,000Direct (D) No
F1
  • F1 25% of the option shares will vest on March 9, 2027, with the remaining option shares to vest in equal monthly installments over the following 36 months, subject to the reporting person providing service through the applicable vesting date.
Open filing 0001808821-26-000006 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-09ARCH Venture Partners IX, LLC 10% ownerARCH Venture Partners IX, L.P. 10% ownerARCH Venture Partners IX Overage, L.P. 10% ownerARCH Venture Fund IX, L.P. 10% ownerARCH Venture Fund IX Overage, L.P. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)488,09025.61
12,499,984.9

Derived: shares × price per share. Exact value 12499984.90.

1,426,528Indirect (I) See footnoteNo
F1
  • F1 These shares are directly held by ARCH Venture Fund XIII, L.P. (ARCH XIII). ARCH Venture Partners XIII, L.P. (AVP XIII LP) is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (AVP XIII LLC) is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the AVP XIII LLC Committee Members). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Open filing 0001012975-26-000235 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-09ARCH Venture Fund XIII, L.P. 10% ownerARCH Venture Partners XIII, L.P. 10% ownerARCH Venture Partners XIII, LLC 10% ownerCRANDELL KEITH 10% ownerNELSEN ROBERT 10% ownerBurow Kristina 10% ownerGILLIS STEVEN 10% ownerBERNS PAUL L 10% ownerBYBEE CLINTON 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)488,09025.61
12,499,984.9

Derived: shares × price per share. Exact value 12499984.90.

1,426,528Indirect (I) See footnoteNo
F1
  • F1 These shares are directly held by ARCH Venture Fund XIII, L.P. (ARCH XIII). ARCH Venture Partners XIII, L.P. (AVP XIII LP) is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (AVP XIII LLC) is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the AVP XIII LLC Committee Members). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Open filing 0001012975-26-000234 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-12Hill Stephen J. Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,23623.39
28,910.04

Derived: shares × price per share. Exact value 28910.04.

17,795Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0001866154-26-000002 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-12Lee Gary K. Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,67123.39
39,084.69

Derived: shares × price per share. Exact value 39084.69.

16,938Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.6305 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0001907345-26-000002 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-12Seely Lynn Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)7,45523.39
174,372.45

Derived: shares × price per share. Exact value 174372.45.

74,266Direct (D) No
F1, F2
  • F1 Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units.
  • F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Open filing 0001327111-26-000002 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-11Lee Gary K. Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)14723.12
3,398.64

Derived: shares × price per share. Exact value 3398.64.

18,609Direct (D) No
F3
  • F3 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0001907345-26-000001 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-11Lee Gary K. Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (50,000) — exercise price 23.71
Acquired (A)50,0000—50,000Direct (D) No
F4
  • F4 Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the Vesting Commencement Date) and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.
Open filing 0001907345-26-000001 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-11Seely Lynn Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)43823.12
10,126.56

Derived: shares × price per share. Exact value 10126.56.

81,721Direct (D) No
F2
  • F2 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0001327111-26-000001 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-11Seely Lynn Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (155,000) — exercise price 23.71
Acquired (A)155,0000—155,000Direct (D) No
F3
  • F3 Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the Vesting Commencement Date) and thereafter, an additional one forty-eighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.
Open filing 0001327111-26-000001 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-11Bulis Veronica Sanchez Officer: VP, Corporate Controller
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)8,7500—15,891Direct (D) No
F1
  • F1 Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan. 12.5% of the total number of restricted stock units will vest on August 9, 2026, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
Open filing 0002095702-26-000002 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-11Bulis Veronica Sanchez Officer: VP, Corporate Controller
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)25423.12
5,872.48

Derived: shares × price per share. Exact value 5872.48.

15,637Direct (D) No
F2
  • F2 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0002095702-26-000002 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-11Meltz Mark A Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (50,000) — exercise price 23.71
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the Vesting Commencement Date) and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.
Open filing 0001771329-26-000001 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-11Shook David Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (50,000) — exercise price 23.71
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the Vesting Commencement Date) and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.
Open filing 0001959742-26-000001 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-11Hill Stephen J. Officer: Chief Operating Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)10923.12
2,520.08

Derived: shares × price per share. Exact value 2520.08.

19,031Direct (D) No
F3
  • F3 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Open filing 0001866154-26-000001 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-11Hill Stephen J. Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option (right to buy) — underlying Common Stock (65,000) — exercise price 23.71
Acquired (A)65,0000—65,000Direct (D) No
F4
  • F4 Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the Vesting Commencement Date) and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.
Open filing 0001866154-26-000001 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–50 of 111

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
ARCH Venture Management, LLC 3,247,162 SH31,789,716 dollarsUnchanged Prior quarter: 3,247,162Open filing 0001012975-26-001080 Filed 2026-11-16 Dispute this row
GSK plc 1,512,659 SH14,808,932 dollarsUnchanged Prior quarter: 1,512,659Open filing 0001999371-26-024635 Filed 2026-11-05 Dispute this row
BlackRock, Inc. Partly reported under another manager799,057 SH7,822,767 dollarsHigher by 74,715 Prior quarter: 724,342Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Orland Properties Ltd Partly reported under another manager754,698 SH7,388,493 dollarsUnchanged Prior quarter: 754,698Open filing 0001193125-26-460134 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 748,848 SH7,331,222 dollarsLower by 37,926 Prior quarter: 786,774Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Decheng Capital LLC 692,050 SH6,775,170 dollarsUnchanged Prior quarter: 692,050Open filing 0001104659-26-127247 Filed 2026-11-13 Dispute this row
Almitas Capital LLC 448,130 SH4,387,193 dollarsLower by 133,277 Prior quarter: 581,407Open filing 0002073679-26-000181 Filed 2026-11-17 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager345,922 SH3,386,576 dollarsNot in the prior quarter’s filings read Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
venBio Partners LLC 337,697 SH3,306,054 dollarsUnchanged Prior quarter: 337,697Open filing 0000905148-26-004927 Filed 2026-11-16 Dispute this row
Alphabet Inc. Partly reported under another manager293,256 SH2,870,976 dollarsUnchanged Prior quarter: 293,256Open filing 0001652044-26-000086 Filed 2026-11-06 Dispute this row
Opaleye Management Inc. 291,353 SH2,852,346 dollarsLower by 52,672 Prior quarter: 344,025Open filing 0001420506-26-002880 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager274,598 SH2,689,337 dollarsLower by 36,038 Prior quarter: 310,636Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
JANE STREET GROUP, LLC Option: Put Partly reported under another manager219,800 SH2,151,842 dollarsNot in the prior quarter’s filings read Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
STATE STREET CORP Partly reported under another manager191,807 SH1,877,791 dollarsHigher by 6,485 Prior quarter: 185,322Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager189,122 SH1,851,504 dollarsHigher by 58,932 Prior quarter: 130,190Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
TWO SIGMA INVESTMENTS, LP 168,122 SH1,645,914 dollarsHigher by 115,195 Prior quarter: 52,927Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
HSG Holding Ltd Partly reported under another manager152,299 SH1,491,007 dollarsUnchanged Prior quarter: 152,299Open filing 0001193125-26-459331 Filed 2026-11-13 Dispute this row
Qube Research Technologies Ltd 142,401 SH1,394,106 dollarsHigher by 31,870 Prior quarter: 110,531Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
MILLENNIUM MANAGEMENT LLC 141,059 SH1,380,968 dollarsLower by 226,414 Prior quarter: 367,473Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager108,541 SH1,062,616 dollarsHigher by 21,762 Prior quarter: 86,779Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager106,744 SH1,045,024 dollarsHigher by 88,049 Prior quarter: 18,695Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager98,662 SH965,900 dollarsLower by 19,838 Prior quarter: 118,500Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager97,951 SH953 dollarsHigher by 38,203 Prior quarter: 59,748Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 93,149 SH911,929 dollarsLower by 14,421 Prior quarter: 107,570Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager89,423 SH875,451 dollarsHigher by 52,373 Prior quarter: 37,050Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
MIC Capital Management UK LLP 87,028 SH852,004 dollarsUnchanged Prior quarter: 87,028Open filing 0001889830-26-000006 Filed 2026-11-13 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 86,227 SH844,162 dollarsLower by 5,664 Prior quarter: 91,891Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
Parkman Healthcare Partners LLC 85,758 SH839,571 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002809 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager84,141 SH823,740 dollarsHigher by 58,159 Prior quarter: 25,982Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
VANGUARD FIDUCIARY TRUST CO 76,187 SH745,871 dollarsLower by 16,908 Prior quarter: 93,095Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Trexquant Investment LP Partly reported under another manager67,175 SH657,643 dollarsNot in the prior quarter’s filings read Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row
XTX Topco Ltd Partly reported under another manager57,903 SH566,870 dollarsNot in the prior quarter’s filings read Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
Point72 Asset Management, L.P. 56,992 SH557,952 dollarsHigher by 30,912 Prior quarter: 26,080Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager49,608 SH477,725 dollarsHigher by 44,812 Prior quarter: 4,796Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager46,434 SH454,248 dollarsLower by 21,881 Prior quarter: 68,315Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
Ikarian Capital, LLC 41,081 SH402,183 dollarsUnchanged Prior quarter: 41,081Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Option: Put Partly reported under another manager39,400 SH385,726 dollarsHigher by 21,500 Prior quarter: 17,900Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Squarepoint Ops LLC Partly reported under another manager39,044 SH382,241 dollarsLower by 3,278 Prior quarter: 42,322Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
Schonfeld Strategic Advisors LLC 38,956 SH381,378 dollarsNot in the prior quarter’s filings read Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row
GSA CAPITAL PARTNERS LLP 38,400 SH376 dollarsHigher by 12,175 Prior quarter: 26,225Open filing 0001362033-26-000013 Filed 2026-11-16 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager36,452 SH356,865 dollarsLower by 9,559 Prior quarter: 46,011Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Verdad Advisers, LP 35,087 SH343,502 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002833 Filed 2026-11-16 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager30,657 SH301 dollarsUnchanged Prior quarter: 30,657Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
CANADA PENSION PLAN INVESTMENT BOARD 29,411 SH287,934 dollarsUnchanged Prior quarter: 29,411Open filing 0001104659-26-128255 Filed 2026-11-16 Dispute this row
RHUMBLINE ADVISERS 25,787 SH252,446 dollarsHigher by 10,325 Prior quarter: 15,462Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager25,411 SH248,774 dollarsHigher by 17,566 Prior quarter: 7,845Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
Empowered Funds, LLC Partly reported under another manager25,171 SH246,424 dollarsNot in the prior quarter’s filings read Open filing 0001592828-26-000008 Filed 2026-11-13 Dispute this row
BRIDGEWAY CAPITAL MANAGEMENT, LLC 25,171 SH246,424 dollarsHigher by 7,171 Prior quarter: 18,000Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Option: Call Partly reported under another manager24,900 SH243,771 dollarsHigher by 7,900 Prior quarter: 17,000Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager24,818 SH242,969 dollarsHigher by 145 Prior quarter: 24,673Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Foresite Capital Management V, LLC 476,386 SH
  • Sixth Street Partners Management Company, L.P. 107,570 SH
  • HRT FINANCIAL LP 36,575 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 25,900 SH
  • EntryPoint Capital, LLC 19,410 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 14,200 SH
  • Graham Capital Management, L.P. 11,602 SH
  • Brevan Howard Capital Management LP 11,557 SH
  • Walleye Capital LLC 10,451 SH
  • LOS ANGELES CAPITAL MANAGEMENT LLC 9,505 SH
  • Truvestments Capital LLC 300 SH
  • GROUP ONE TRADING LLC 100 SH
  • GROUP ONE TRADING LLC 88 SH
  • Optiver Holding B.V. 20 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
ARCH Venture Fund IX, L.P. Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
ARCH Venture Fund IX Overage, L.P. Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
ARCH Venture Fund XIII, L.P. Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
ARCH Venture Partners IX, L.P. Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
ARCH Venture Partners IX Overage, L.P. Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
ARCH Venture Partners IX, LLC Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
ARCH Venture Partners XIII, L.P. Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
ARCH Venture Partners XIII, LLC Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
Keith Crandell Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
Clinton Bybee Common Stock par value $0.0001 per share5.71,820,63411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
Robert Nelsen Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
Kristina Burow Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
Steven Gillis Common Stock par value $0.0001 per share17.45,568,42411/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
Paul Berns Common Stock par value $0.0001 per share11.73,747,79011/04/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-001025 Dispute this row
Foresite Capital Fund IV, L.P. Common Stock, par value $0.00010.00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097073 Dispute this row
Foresite Capital Management IV, LLC Common Stock, par value $0.00010.00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097073 Dispute this row
Foresite Capital Fund V, L.P. Common Stock, par value $0.00011.9476,386.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097073 Dispute this row
Foresite Capital Management V, LLC Common Stock, par value $0.00011.9476,386.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097073 Dispute this row
Foresite Capital Opportunity Fund V, L.P. Common Stock, par value $0.00010.7176,942.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097073 Dispute this row
Foresite Capital Opportunity Management V, LLC Common Stock, par value $0.00010.7176,942.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097073 Dispute this row
James B. Tananbaum Common Stock, par value $0.00012.7653,328.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001104659-26-097073 Dispute this row
Innovative Cellular Therapeutics Holdings Limited Common Stock, par value $0.000112.33,000,00005/18/2026 Filed 2026-06-18SCHEDULE 13G/AAmendment 1Open filing 0001140361-26-025769 Dispute this row
ARCH Venture Fund IX, L.P. Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
ARCH Venture Fund IX Overage, L.P. Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
ARCH Venture Fund XIII, L.P. Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
ARCH Venture Partners IX, L.P. Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
ARCH Venture Partners IX Overage, L.P. Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
ARCH Venture Partners IX, LLC Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
ARCH Venture Partners XIII, L.P. Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
ARCH Venture Partners XIII, LLC Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
Keith Crandell Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
Clinton Bybee Common Stock par value $0.0001 per share7.81,820,63403/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
Robert Nelsen Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
Kristina Burow Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
Steven Gillis Common Stock par value $0.0001 per share13.93,247,16203/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
Paul Berns Common Stock par value $0.0001 per share6.11,426,52803/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-000439 Dispute this row
MWG Caph Ltd Common Stock, $0.0001 par value per share4.31,008,11603/31/2026 Filed 2026-05-11SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-216076 Dispute this row
Milky Way Investments Group Ltd. Common Stock, $0.0001 par value per share4.31,008,11603/31/2026 Filed 2026-05-11SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-216076 Dispute this row
Explore Investments LLC Common Stock, par value $0.0001 per share6.61,529,054.0003/31/2026 Filed 2026-05-08SCHEDULE 13G/AAmendment 1Open filing 0001168404-26-000021 Dispute this row
Jeffrey P. Bezos Common Stock, par value $0.0001 per share6.61,529,054.0003/31/2026 Filed 2026-05-08SCHEDULE 13G/AAmendment 1Open filing 0001168404-26-000021 Dispute this row
EULER FUND, L.P. Common Stock6.711,426,52803/06/2026 Filed 2026-04-21SCHEDULE 13GOpen filing 0001193125-26-165277 Dispute this row
Euler Managers Limited Common Stock6.711,426,52803/06/2026 Filed 2026-04-21SCHEDULE 13GOpen filing 0001193125-26-165277 Dispute this row
Antonis Indianos Common Stock6.711,426,52803/06/2026 Filed 2026-04-21SCHEDULE 13GOpen filing 0001193125-26-165277 Dispute this row
Innovative Cellular Therapeutics Holdings Ltd Common Stock, par value $0.00019.81,900,00011/06/2025 Filed 2025-11-13SCHEDULE 13GOpen filing 0001140361-25-042006 Dispute this row
Foresite Capital Fund IV, L.P. Common Stock, par value $0.00014.2800,339.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-112479 Dispute this row
Foresite Capital Management IV, LLC Common Stock, par value $0.00014.2800,339.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-112479 Dispute this row
Foresite Capital Fund V, L.P. Common Stock, par value $0.00012.5477,078.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-112479 Dispute this row
Foresite Capital Management V, LLC Common Stock, par value $0.00012.5477,078.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-112479 Dispute this row
Foresite Capital Opportunity Fund V, L.P. Common Stock, par value $0.00010.9177,199.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-112479 Dispute this row
Foresite Capital Opportunity Management V, LLC Common Stock, par value $0.00010.9177,199.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-112479 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,540,664 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020166,957
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to Lyell Immunopharma, Inc.